Form 4: Esperion Therapeutics Executive Benjamin Looker Reports Stock Grant and Option Award

Benjamin Looker, General Counsel of Esperion Therapeutics, reports the acquisition of 100,000 shares of common stock and an option to purchase 150,000 shares.

Summary

• On March 14, 2024, Benjamin Looker, General Counsel of Esperion Therapeutics, Inc., reported a transaction involving the company's securities.
• Looker acquired 100,000 shares of common stock at $0 price.
• Following the transaction, Looker directly owns 183,663 shares of Esperion Therapeutics.
• Looker was also granted an option to purchase 150,000 shares of common stock at an exercise price of $2.05.
• The options vest in equal quarterly installments over a four-year period, starting June 15, 2024, and expire on March 14, 2034.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The grant of stock and options could be viewed as a positive sign of alignment between management and shareholders, but it's a routine event.

Positives

• The grant of stock and options to a key executive could be seen as an incentive to align their interests with the company's long-term success.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedule of the options suggests a long-term commitment from the executive.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry, similar to companies like Amgen, Regeneron, and Vertex Pharmaceuticals.
• The vesting schedule of four years with quarterly installments is also a typical arrangement.

Stakeholder Impact

• Shareholders may view the stock and option grants as a way to incentivize management to improve company performance.
• Employees may see this as a positive sign of the company investing in its leadership.

Key Dates